Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC. Background: First-line treatment with immunotherapy has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback